New vaccine shows promise against Traveler's diarrhea in early trial

NCT ID NCT06692907

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental vaccine (CssBA+dmLT) to see if it can prevent moderate-to-severe diarrhea caused by ETEC bacteria, a common cause of traveler's diarrhea. About 72 healthy adults received either the vaccine or a placebo, then were exposed to the bacteria in a controlled setting. The goal was to measure how well the vaccine protects against diarrhea and to check for any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESCHERICHIA INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diarrheal disease escherichia coli infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESCHERICHIA INFECTION

Contacts and locations

Show contact details

Locations

Cincinnati Children's Hospital Medical Center Vaccine Research Center

Cincinnati, Ohio, 45229-3039, United States
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health

Baltimore, Maryland, 21201-1509, United States